FDA experts offer a big thumbs up for J&J’s flawed application for ketamine-based depression drug — but trial failures, safety questions spur concerns
J&J may have a deeply flawed application for its new/old drug to treat major depression, but the researchers who turned out to present the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
